U.S. flag

An official website of the United States government

Format
Items per page
Sort by

Send to:

Choose Destination

Links from GEO DataSets

Items: 10

1.

Shrinking the Psoriasis assessment gap: Early gene-expression profiling accurately predicts response to long-term treatment

(Submitter supplied) Prediction of response to adalimumab and methotrexate treatments based on gene expression profiles at baseline, weeks 1, 2, 4 and 16
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL10558
179 Samples
Download data: TXT
Series
Accession:
GSE85034
ID:
200085034
2.

Pathologic Immune Pathways in Psoriasis are Rapidly Attenuated by Tofacitinib Treatment: A Randomized Phase 2 Study in Patients with Moderate to Severe Psoriasis

(Submitter supplied) Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. We sought to elucidate the molecular mechanisms underlying the clinical efficacy of tofacitinib in patients with psoriasis. Twelve patients with plaque psoriasis were randomized (3:1) to receive 10 mg of tofacitinib or placebo twice daily for 12 weeks. Biopsy specimens were taken from nonlesional (baseline) and lesional (baseline, days 1 and 3, and weeks 1, 2, 4, and 12) skin. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
95 Samples
Download data: CEL
Series
Accession:
GSE69967
ID:
200069967
3.

A Randomized, Placebo-Controlled Study to Evaluate SRT2104, a Selective SIRT1 Activator, in Patients with Moderate to Severe Psoriasis

(Submitter supplied) Activation of Sirtuin (silent mating type information regulation 2 homolog) 1, or SIRT1, is an unexplored therapeutic approach for treatment of inflammatory diseases. The goal of this study was to evaluate the clinical activity and tolerability of multiple doses of SRT2104, a selective activator of SIRT1, in patients with moderate to severe psoriasis after day 84 of treatment. Forty patients were randomized 4:1 to three escalating doses of SRT2104 (250, 500, 1000 mg/d SRT2104 or placebo). more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
22 Samples
Download data: CEL
Series
Accession:
GSE50614
ID:
200050614
4.

Expression data from skin biopsy samples from patients with moderate-to-severe psoriasis

(Submitter supplied) A gene expression profiling sub-study was conducted in which skin biopsy samples were collected from 85 patients with moderate-to-severe psoriasis who were participating in ACCEPT, an IRB-approved Phase 3, multicenter, randomized trial. This analysis identified 4,175 probe-sets as being significantly modulated in psoriasis lesions (LS) compared with matched biopsies of non-lesional (NL) skin.
Organism:
Homo sapiens
Type:
Expression profiling by array
Dataset:
GDS4600
Platform:
GPL570
170 Samples
Download data: CEL
Series
Accession:
GSE30999
ID:
200030999
5.

Effective treatment of psoriasis with etanercept is linked to suppression of IL17 signaling, not immediate response TNF

(Submitter supplied) The success of TNF inhibitors for treatment of psoriasis and other inflammatory diseases was previously attributed to blockade of innate immunity. In a clinical trial using etanercept TNF blocking agent to treat psoriasis vulgaris, we used affymetrix gene arrays to analyze broad gene profiles in lesional skin at multiple timepoints during drug treatment (baseline, and weeks 1, 2, 4 and 12) compared to non-lesional skin. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL571
89 Samples
Download data: CEL
Series
Accession:
GSE11903
ID:
200011903
6.
Full record GDS4600

Psoriasis vulgaris ACCEPT cohort: paired lesional and non-lesional skin

Analysis of 85 paired lesional and non-lesional samples from moderate-to-severe psoriasis patients at baseline without active psoriasis therapy. Results provide insight into the molecular mechanisms underlying psoriasis.
Organism:
Homo sapiens
Type:
Expression profiling by array, transformed count, 2 disease state, 33 individual, 82 other, 10 specimen sets
Platform:
GPL570
Series:
GSE30999
170 Samples
Download data: CEL
7.

Early quantification of systemic inflammatory (INF) and cardiovascular disease (CVD) proteins predicts long-term treatment response to Tofacitinib and Etanercept

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Other
Platforms:
GPL27152 GPL27151
1020 Samples
Download data
Series
Accession:
GSE136435
ID:
200136435
8.

Early quantification of systemic inflammatory (INF) and cardiovascular disease (CVD) proteins predicts long-term treatment response to Tofacitinib and Etanercept (INF data set)

(Submitter supplied) Proteomic profiles of 92 inflammatory proteins were measured in the blood of psoriasis patients both before and after treatment with tofacitanib or etanercept. These proteomic profiles were used to develop statistical classifiers for predicting PASI75 responses to tofacitinib and etancercept
Organism:
Homo sapiens
Type:
Other
Platform:
GPL27152
528 Samples
Download data: XLSX
Series
Accession:
GSE136434
ID:
200136434
9.

Early quantification of systemic inflammatory (INF) and cardiovascular disease (CVD) proteins predicts long-term treatment response to Tofacitinib and Etanercept (CVD data set)

(Submitter supplied) Proteomic profiles of 91 cardiovascular disease proteins were measured in the blood of psoriasis patients both before and after treatment with tofacitanib or etanercept. These proteomic profiles were used to develop statistical classifiers for predicting PASI75 responses to tofacitinib and etancercept
Organism:
Homo sapiens
Type:
Other
Platform:
GPL27151
492 Samples
Download data: XLSX
Series
Accession:
GSE136431
ID:
200136431
10.

MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis

(Submitter supplied) Background: Psoriasis is a systemic inflammatory skin disease. MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that recently have been found in the blood to be relevant as disease biomarkers. Objective: We aimed to explore miRNAs potential as blood biomarkers for psoriasis. Methods: Using microarray and quantitative real-time PCR we measured the global miRNA expression in whole blood, plasma and peripheral blood mononuclear cells (PBMCs) from patients with psoriasis and healthy controls. more...
Organism:
Homo sapiens; Mus musculus; Rattus norvegicus
Type:
Non-coding RNA profiling by array
Platform:
GPL11241
34 Samples
Download data: TXT
Series
Accession:
GSE55515
ID:
200055515
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

db=gds|term=|query=1|qty=4|blobid=MCID_6731d144f73b361c515a8c96|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center